Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Provectus Biopharmaceuticals, Inc. (PVCT : OTC)
 
 • Company Description   
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.06 Daily Weekly Monthly
20 Day Moving Average: 242,676 shares
Shares Outstanding: 420.28 (millions)
Market Capitalization: $26.90 (millions)
Beta: 0.50
52 Week High: $0.15
52 Week Low: $0.06
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.04% -15.32%
12 Week -26.01% -29.08%
Year To Date -46.71% -53.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
800 S Gay Street Suite 1610
-
KNOXVILLE,TN 37929
USA		 ph: 866-594-5999
fax: 866-998-0005		 investorrelations@pvct.com http://www.provectusbio.com
 
 • General Corporate Information   
Officers
Ed Pershing - CEO and Director and Chairman of the Board
Dominic Rodrigues - President and Director; Vice Chairman of the Board
Heather Raines - Chief Financial Officer
Webster Bailey - Director
John W. Lacey, III - Director

Peer Information
Provectus Biopharmaceuticals, Inc. (CORR.)
Provectus Biopharmaceuticals, Inc. (RSPI)
Provectus Biopharmaceuticals, Inc. (CGXP)
Provectus Biopharmaceuticals, Inc. (BGEN)
Provectus Biopharmaceuticals, Inc. (GTBP)
Provectus Biopharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74373P108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/11/25
Share - Related Items
Shares Outstanding: 420.28
Most Recent Split Date: (:1)
Beta: 0.50
Market Capitalization: $26.90 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/11/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 58.35
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -77.25%
vs. Previous Quarter: -79.21%
ROE
09/30/25 - -
06/30/25 - -
03/31/25 - -
ROA
09/30/25 - -
06/30/25 - -792.87
03/31/25 - -644.80
Current Ratio
09/30/25 - -
06/30/25 - 0.09
03/31/25 - 0.11
Quick Ratio
09/30/25 - -
06/30/25 - 0.09
03/31/25 - 0.11
Operating Margin
09/30/25 - -
06/30/25 - -1,374.19
03/31/25 - -815.81
Net Margin
09/30/25 - -
06/30/25 - -1,374.19
03/31/25 - -815.81
Pre-Tax Margin
09/30/25 - -
06/30/25 - -1,393.71
03/31/25 - -823.71
Book Value
09/30/25 - -
06/30/25 - -0.01
03/31/25 - -0.01
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Capital
09/30/25 - -
06/30/25 - -
03/31/25 - -
 

Powered by Zacks Investment Research ©